AlphAIAlphAI — Financial news for AI agents
tradingview.comAUG 71 min read$RYN

Rayonier Inc. REIT Stock 12‑Month Price Target Raised to $26, Implies 21% Upside

Analyst estimates for Rayonier Inc. REIT show its 12-month average price target increased to $26 from $25.83, based on six analysts. Targets range from $23 to $32. Using the Aug. 6 closing price, the update implies about 21% upside. The consensus rating remains “Buy” with 2 Buys, 4 Holds, and 0 Sells.

Original reporting
tradingview.com
Published Aug 7, 2026, 11:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 8, 2026, 7:37 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Rayonier Inc. REIT Stock 12‑Month Price Target Raised to $26, Implies 21% Upside — source image
Source · tradingview.com
Decision brief

The 30-second read

$RYNBullishLow
01

Why it matters

The only actionable signal is sentiment from analyst target revision (average target up to $26) and the implied upside versus the Aug. 6 close; no new company-specific operational or financial disclosure is provided.

02

Market read

Traders may treat this as a mild bullish sentiment update, but it lacks the detail needed for a high-conviction trade.

03

What to watch

The article does not specify the reason for the target increase, nor whether any analyst changed earnings estimates, so traders should verify the underlying assumptions before acting.

Relevance 4/10Novelty 4/10Timing: post-close context around the Aug. 6 reference price target update

Background

The piece summarizes FactSet-based analyst consensus for Rayonier Inc. REIT, focusing on the updated 12-month price target and rating distribution.

Company-level read

Ticker impact

$RYNBullishMedium confidence
Context

Rayonier Inc. REIT’s 12-month average analyst price target rose from $25.83 to $26, implying about 21% upside from the Aug. 6 close.

Expected impact

Likely modest near-term support from sentiment/positioning, with limited follow-through unless additional upgrades or new fundamentals emerge.

Evidence & confidence

The article only reports analyst target revisions and consensus mix (Buy/Hold), with no new guidance, earnings, or operational catalyst disclosed.

Market effects

Sector

Minimal. Analyst target changes for a single REIT do not materially reset sector fundamentals in the text.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A raised target can reflect model assumptions rather than improved fundamentals, so the stock may not re-rate if the underlying thesis is unchanged.

Key entities

  • public_company
    Rayonier Inc. REIT

    Subject of the article, with consensus 12-month price target raised to $26 and Buy/Hold mix unchanged at 6 analysts.

Read at source← All news

Related articles

AUG 13
$RYNMed

Rayonier (RYN) Q2 2026 Earnings Call Transcript

Rayonier (RYN) reported Q2 2026 results during its earnings call, citing net income attributable to $19.1M ($0.06/share) and pro forma net income of $31.5M ($0.10/share). Adjusted EBITDA was $123.7M, boosted by PotlatchDeltic integration. Lumber price realization averaged $505/MBF. The company repurchased 3.5M shares for $72.4M and guided harvest and real estate EBITDA.

fool.com7 min
AUG 9
$RYNMed

Rayonier Q2 Earnings Call Highlights

Rayonier (NYSE: RYN) reported Q2 segment updates on its earnings call. Southern Timber adjusted EBITDA rose to $53M, Northwest Timber to $26M, and Wood Products adjusted EBITDA was $25M. Real estate revenue was $54M. The company repurchased 3.5M shares for $72M, ended with $412M cash, and guided full-year harvest volumes and Real Estate adjusted EBITDA of $180M-$200M.

yahoo.com7 min
OCT 8
$LLYLow

Nektar v. Lilly: Lilly Defeats CRE Claim, But Jury Finds It Owes $90M For Breaching The Implied Covenant Of Good Faith And Fair Dealing

A federal jury ruled that Eli Lilly & Co. breached the implied covenant of good faith and fair dealing with Nektar Therapeutics, awarding Nektar $90 million in damages. The jury rejected Nektar's claim that Lilly breached the license agreement's commercially reasonable efforts (CRE) obligation. Lilly plans to appeal, arguing no liability should have been imposed. The case highlights risks in biopharma licensing agreements.

mondaq.com2 min
OCT 8
$EQNRMed

Galp Energia and Equinor Get Offshore Brazilian Oil Block

Galp Energia and Equinor have been awarded an offshore oil block in Brazil's Santos Basin. Galp will own 30% of the Rodocrosita block, with Equinor operating the remaining 70%. The companies may explore synergies with the adjacent Bacalhau project, which is ramping up production and will contribute 40,000 barrels per day to Galp once fully operational.

marketscreener.com1 min
OCT 8
$PINSMed

Pinterest (PINS), Why Is It Back In The Spotlight?

Pinterest (PINS) appointed Amazon's James Dibbo as its new CFO. The company's stock has shown mixed performance, with a recent 7-day return of 7.52% but a 1-year return of -36.11%. Analysts have varying views on its valuation, with some seeing it as undervalued at $20.31 per share compared to a fair value estimate of $29.05, while others note its high P/E ratio of 46.2x.

simplywall.st2 min